GlycoEra AG

GlycoEra has extensive experience in sugar engineering, protein degradation and the development of biopharmaceuticals. Based on this expertise, GlycoEra has developed a platform that makes it possible to produce protein binders with precisely defined sugar structures that utilise the body’s own efficient degradation processes. This technology enables rapid, targeted and potent degradation of disease-associated circulating proteins and opens up new applications in precision immunology and the potential treatment of severe autoimmune diseases. Clinical testing of the first product candidates is planned for the end of 2025. GlycoEra AG has sites in Wädenswil, Switzerland, and Newton, Massachusetts, USA.